Shivdasani R A, Fielder P, Keller G A, Orkin S H, de Sauvage F J
Department of Medicine, Dana-Farber Cancer Institute, Children's Hospital Medical Center, and Harvard Medical School, Boston, MA 02115, USA.
Blood. 1997 Sep 1;90(5):1821-7.
The mechanisms that regulate circulating levels of thrombopoietin (Tpo) are incompletely understood. According to one favored model, the rate of Tpo synthesis is constant, whereas the serum concentration of free Tpo is modulated through binding to c-Mpl receptor expressed on blood platelets. Additionally, a role for c-Mpl expressed on megakaryocytes is suggested, particularly by the observation that serum Tpo levels are not elevated in human immune thrombocytopenic purpura. Whereas direct binding of Tpo to platelets has been demonstrated in vitro and in vivo, the role of megakaryocytes in modulating serum Tpo levels has not been addressed experimentally. The profoundly thrombocytopenic mice lacking transcription factor p45 NF-E2 do not show the predicted increase in serum Tpo concentration. To evaluate the fate of the ligand in these animals, we injected 125I-Tpo intravenously into mutant and control mice. In contrast to normal littermates, NF-E2 knockout mice show negligible association of radioactivity with blood cellular components, consistent with an absence of platelets. There is no corresponding increase in plasma-associated radioactivity to suggest persistence in the circulation. However, a greater fraction of the radioligand is bound to hematopoietic tissues. In the bone marrow this is detected virtually exclusively in association with megakaryocytes, whereas in the spleen it is associated with megakaryocytes and small, abnormal, platelet-like particles or megakaryocyte fragments that are found within or in close contact with macrophages. These findings implicate the combination of megakaryocytes and the latter particles as a sink for circulating Tpo in NF-E2 knockout mice, and provide an explanation for the lack of elevated serum Tpo levels in this unique animal model of thrombocytopenia.
调节血小板生成素(Tpo)循环水平的机制尚未完全明确。根据一种流行的模型,Tpo的合成速率是恒定的,而游离Tpo的血清浓度则通过与血小板上表达的c-Mpl受体结合来调节。此外,有人提出巨核细胞上表达的c-Mpl也发挥作用,特别是基于人类免疫性血小板减少性紫癜患者血清Tpo水平未升高这一观察结果。虽然已在体外和体内证实Tpo能直接与血小板结合,但巨核细胞在调节血清Tpo水平中的作用尚未通过实验进行研究。缺乏转录因子p45 NF-E2的严重血小板减少小鼠并未出现预期的血清Tpo浓度升高。为了评估这些动物体内配体的去向,我们将125I-Tpo静脉注射到突变小鼠和对照小鼠体内。与正常同窝小鼠相比,NF-E2基因敲除小鼠的放射性与血细胞成分的结合可忽略不计,这与血小板缺失一致。血浆相关放射性没有相应增加,表明其在循环中未持续存在。然而,更大比例的放射性配体与造血组织结合。在骨髓中,几乎仅在与巨核细胞相关的部位检测到放射性配体,而在脾脏中,它与巨核细胞以及在巨噬细胞内或与之紧密接触的小的、异常的、血小板样颗粒或巨核细胞碎片相关。这些发现表明,在NF-E2基因敲除小鼠中,巨核细胞与后一种颗粒的结合构成了循环Tpo的一个“汇”,并为这种独特的血小板减少动物模型中血清Tpo水平未升高提供了解释。